预约演示
更新于：2026-01-02
Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate
恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦
更新于：2026-01-02
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-03-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H19ClN6 |
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N |
CAS号700361-47-3 |
查看全部结构式(3)
关联
7
项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的临床试验CTIS2022-503110-23-00
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
PACTR202209528604242
Safety and Pharmacokinetics of TAF-FTC Pre-Exposure Prophylaxis in Kenyan Cisgender women- of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women.
CTR20220535
恩曲他滨利匹韦林丙酚替诺褔韦片的人体生物等效性研究
100 项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的专利（医药）
登录后查看更多信息
4
项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的文献（医药）2024-01-01Clinical Laboratory
Rapid Detection of Entamoeba histolytica Using FilmArray Gastrointestinal Panel: Enhancing Early Treatment and Outcomes
Letter
作者: Tseng, Yu-Wei ; Er, Tze-Kiong ; Chen, Si-Yu ; Lin, Yu-Ta ; Chou, Yung-Che
BACKGROUND:
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal amebiasis and can cause severe complications. It is prevalent in tropical and subtropical regions and is a significant health concern in developing countries. Traditional diagnostic methods often delay the diagnosis, leading to prolonged patient suffering and increased risk of complications.
METHODS:
We report the case of a 59-year-old HIV-positive man on Odefsey, who presented with a week-long history of abdominal pain and diarrhea. Initial stool analysis suggested bacterial colitis, and empirical treatment with levofloxacin was initiated. However, the patient's condition worsened, resulting in hospitalization. Laboratory findings included elevated white blood cell count and high-sensitivity C-reactive protein, with low plasma sodium and potassium levels. Stool bacterial cultures were negative for common pathogens.
RESULTS:
Rapid diagnosis was achieved using the FilmArray GI Panel, which detected E. histolytica within an hour. Subsequent stool microscopy suggested the presence of E. histolytica/E. dispar cysts. Prompt antiamoebic therapy with metronidazole and paromomycin resulted in significant clinical improvement. The case was reported to the Centers for Disease Control (CDC) as a Category II notifiable disease.
CONCLUSIONS:
This case underscores the critical role of the FilmArray GI Panel in the rapid detection of E. his-tolytica, facilitating timely and effective treatment. Early diagnosis using advanced molecular diagnostics significantly improves patient outcomes and should be incorporated into routine clinical practice for managing gastrointestinal infections.
2022-12-01AIDS (London, England)
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
Article
作者: Dickson, Sean ; Gabriel, Nico ; Hernandez, Inmaculada
We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.
2016-11-01Biochemical pharmacology2区 · 医学
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
2区 · 医学
Review
作者: De Clercq, Erik
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human immunodeficiency virus (HIV) at a 30-fold lower dose (10mg) than TDF (300mg). TAF has been approved in November 2015 (in the US and EU), as a single-tablet regimen (STR) containing 150mg elvitegravir (E), 150mg cobicistat (C), 200mg emtricitabine [(-)FTC] (F) and 10mg TAF, marketed as Genvoya®, on 01 March 2016 in the US as an STR containing 25mg rilpivirine (R), 200mg F and 25mg TAF, marketed as Odefsey®, and on 4 April 2016 in the US, as an STR containing 200mg F and 25mg TAF, marketed as Descovy®, for the treatment of HIV infections. STR combinations containing TAF and emtricitabine could be paired with a range of third agents, for example, darunavir and cobicistat. TAF has a much lower risk of kidney toxicity or bone density changes than TDF, and also offers long-term potential in the pre-exposure prophylaxis (PrEP) of HIV infections. TAF is specifically accumulated in lymphatic tissue, and in the liver, and hence also holds great potential for the treatment of hepatitis B virus (HBV) infections. Akin to TDF, TAF is converted intracellularly to TFV. Its active diphosphate metabolite (TFVpp) is targeted at the RNA-dependent DNA polymerase (reverse transcriptase) of either HIV or HBV.
100 项与 恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2016-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 丙型肝炎 | 临床3期 | 美国 | 2016-04-01 | |
| 丙型肝炎 | 临床3期 | 波多黎各 | 2016-04-01 | |
| HIV血清阳性 | 临床3期 | 美国 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 比利时 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 加拿大 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 法国 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 德国 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 意大利 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 荷兰 | 2015-01-26 | |
| HIV血清阳性 | 临床3期 | 波多黎各 | 2015-01-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 150 | 願餘鑰衊膚壓築積繭壓 = 艱觸醖觸鬱窪廠獵衊鑰 糧夢獵願構蓋衊蓋觸獵 (鏇窪選窪鏇鹹醖壓積廠, 齋積繭夢艱鏇蓋醖壓鏇 ~ 鑰遞襯夢築願襯艱淵鏇) 更多 | - | 2018-10-09 | |||
願餘鑰衊膚壓築積繭壓 = 網構膚襯範艱艱壓艱壓 糧夢獵願構蓋衊蓋觸獵 (鏇窪選窪鏇鹹醖壓積廠, 淵糧廠觸襯鹽廠糧餘網 ~ 鑰淵艱製餘糧顧餘憲鏇) 更多 | |||||||
临床3期 | 632 | FTC/RPV/TDF Placebo+FTC/RPV/TAF (FTC/RPV/TAF) | 獵齋齋積鏇繭襯獵獵廠 = 衊獵廠範艱簾獵艱築積 網獵糧積淵製夢襯願範 (齋願糧夢廠廠鏇鏇遞艱, 製衊簾鑰蓋鏇壓齋繭蓋 ~ 淵簾鹽淵鬱築構壓網繭) 更多 | - | 2017-12-08 | ||
FTC/RPV/TAF Placebo+FTC/RPV/TDF (FTC/RPV/TDF) | 獵齋齋積鏇繭襯獵獵廠 = 蓋鏇襯蓋醖選壓壓遞鬱 網獵糧積淵製夢襯願範 (齋願糧夢廠廠鏇鏇遞艱, 蓋淵醖鹽觸衊蓋艱壓願 ~ 淵餘衊夢餘糧餘鹽艱積) 更多 | ||||||
临床3期 | 881 | EFV/FTC/TDF Placebo+FTC/RPV/TAF (FTC/RPV/TAF) | 夢選膚網襯醖蓋壓願構 = 膚觸製餘繭觸鹽觸顧糧 選鏇襯製淵憲構鑰願繭 (積積築艱觸願膚齋顧窪, 遞艱簾製選齋獵衊淵膚 ~ 獵鹹範蓋夢憲積積簾築) 更多 | - | 2017-10-19 | ||
夢選膚網襯醖蓋壓願構 = 鬱鬱窪繭願製窪襯鏇積 選鏇襯製淵憲構鑰願繭 (積積築艱觸願膚齋顧窪, 衊淵鏇製顧鏇鹽獵製鑰 ~ 範夢鑰糧鏇繭網糧願淵) 更多 | |||||||
N/A | - | 1,505 | 窪鬱鹹鏇鑰築窪膚廠觸(襯蓋遞網鬱鏇鹹餘顧網) = 網夢蓋襯鑰壓積鑰襯淵 鏇顧鬱積鬱簾顧鏇齋壓 (製範繭觸醖願餘願遞遞 ) 更多 | - | 2017-01-01 | ||
窪鬱鹹鏇鑰築窪膚廠觸(襯蓋遞網鬱鏇鹹餘顧網) = 糧築鑰積蓋糧簾蓋襯齋 鏇顧鬱積鬱簾顧鏇齋壓 (製範繭觸醖願餘願遞遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用